U.S. Food and Drug Administration approves extended dosing for EYLEA HD up to 20 weeks in wAMD and DME, supported by 2-year PULSAR and PHOTON trial data showing sustained efficacy and safety.
Written By: Mahathi Palivela, PharmD
Reviewed By: Pharmacally Editorial Team
U.S. Food and Drug Administration has approved an update to the dosing schedule of EYLEA HD (aflibercept), allowing treatment intervals of up to every 20 weeks in patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) who have demonstrated a successful response after one year of therapy.
The approval also includes updates to the prescribing information incorporating 96-week data from the pivotal PULSAR trial and PHOTON trial, confirming sustained efficacy and safety over two years with extended dosing intervals.
Durable Efficacy Supports Extended Treatment Intervals
The updated label reflects long-term outcomes showing that most patients maintained or further extended dosing intervals through 96 weeks while preserving visual and anatomical improvements achieved during the first year.
At week 96, 71% of patients with wet age-related macular degeneration (wAMD) achieved dosing intervals of at least 16 weeks and 47% reached 20 weeks, while in diabetic macular edema (DME), 72% reached at least 16-week intervals and 44% achieved 20-week intervals.
These findings support a flexible, individualized treatment approach, allowing dosing as frequently as every four weeks or as infrequently as every 20 weeks based on disease activity and patient response.
Expanding Flexibility in Anti-VEGF Treatment
With this update, EYLEA HD now offers the widest approved dosing range among injectable anti-VEGF therapies. The extended interval option is expected to reduce treatment burden for patients who achieve stable disease control after initial therapy.
Clinicians noted that the ability to reduce injections to as few as two or three per year could improve adherence and long-term management, particularly in patients requiring chronic treatment.
Safety Profile Remains Consistent
The safety profile of EYLEA HD remained consistent with previous data. The most commonly reported adverse events (≥3%) included cataract, conjunctival hemorrhage, increased intraocular pressure, ocular discomfort such as eye pain or irritation, retinal hemorrhage, blurred vision, as well as vitreous detachment and vitreous floaters.
Regulatory and Development Updates
In addition to the dosing update, the FDA is reviewing a prefilled syringe version of EYLEA HD, with a target action date set for April 2026.
Trial Design and Disease Context
Both PULSAR (NCT04423718) and PHOTON (NCT04429503) were global, double-masked, active-controlled trials evaluating extended dosing regimens of EYLEA HD compared with standard EYLEA dosing. Patients initially received monthly loading doses, followed by interval adjustments based on disease activity.
wAMD is characterized by abnormal blood vessel growth under the retina, leading to fluid leakage and vision loss. DME arises from diabetic retinal damage, where leaking blood vessels cause retinal swelling and visual impairment.
Advancing Long-Acting Retinal Therapies
EYLEA HD builds on the established anti-VEGF mechanism of aflibercept, designed to maintain comparable efficacy to standard-dose therapy while reducing injection frequency. The therapy is jointly developed by Regeneron and Bayer, with Regeneron holding U.S. rights and Bayer managing markets outside the United States.
The latest approval reinforces the shift toward longer-acting retinal therapies aimed at balancing durable disease control with reduced treatment burden.
Reference
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME), 02 April 2026, EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) | Regeneron Pharmaceuticals Inc.
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR), ClinicalTrials.gov ID NCT04423718, https://clinicaltrials.gov/study/NCT04423718
Study of a High-Dose Aflibercept in Participants with Diabetic Eye Disease (PHOTON), ClinicalTrials.gov ID NCT04429503, https://clinicaltrials.gov/study/NCT04429503
Mahathi Palivela is pursuing a PharmD and has a strong interest in clinical pharmacy and patient safety. She is passionate about handling and analyzing patient data, and translating clinical insights into clear, meaningful summaries. She aims to apply this interest in medical writing and pharmacovigilance, focusing on improving patient outcomes through careful data interpretation and communication